Funding This work was supported by research funding to the institution from Merck, Astellas, Lepu Biopharma, Amgen, Revolution Medicines, Break Through Cancer, Parker Institute, and The Society of MSK; NIH Pancreas SPORE (1P50CA257881-01A1); NIH K12 CA184746 Paul Calabresi Career Development Award for Clinical Oncology; MSK Parker Institute for Cancer Immunotherapy Pilot Grant Award; Merck Investigator Studies Program; Break Through Cancer – Conquering KRAS for Pancreatic Cancer and Demystifying Pancreatic Cancer Therapies (W.P.). Here, KRAS is linked to pancreatic neoplasm.